Ruxolitinib in severe COVID-19
Results of a multicenter, prospective, single arm, open-label clinical study to investigate the efficacy and safety of ruxolitinib in patients with COVID-19 and severe acute respiratory syndrome
DOI:
https://doi.org/10.31053/1853.0605.v78.n3.32800Keywords:
coronavirus infections, Janus kinase inhibitors, respiratory distress syndrome, adultAbstract
Introduction: COVID-19 morbimortality is mainly associated with development of severe acute respiratory syndrome (SARS), which has been related to an augmented immune response of the host with elevated circulating cytokines. Methods: In this is a prospective, multicenter, single arm (compared with a historical control), add-on, experimental phase 2 study, ruxolitinib 5 mg BID was added to standard of care in COVID-19 patients. Main objective was to determine efficacy and safety of ruxolitinib in patients with COVID-19-related SARS. Results: Even though we could not show a significant reduction of COVID-19 pneumonia patients requiring intensive care unit admission and mechanical ventilation (primary endpoint), a trend to a lower mortality rate in critical ill patients receiving ruxolitinib was reported. Administered ruxolitinib dose had to be increased according to protocol in 32% of patients, without additional toxicity. Conclusion: Side effects profile was manageable, and no direct organ injury was caused by the study drug. Ruxolitinib had a fast anti-inflammatory effect, and one-third of patients felt well immediately after starting treatment.
Downloads
References
World Health Organization. Virtual press conference on COVID-19. 2020 Mar. Available at: https://bit.ly/3gg2mrf
Johns Hopkins University and Medicine. Coronavirus Resource Center. Available at: https://bit.ly/2JURG57
Castaneda C, Ah Rhee CJ, Magh A, Eng C, Mann J, Sanso L, Abe O. Impact of ventilator model on mortality: a retrospective cross-sectional study in 147 mechanically ventilated patients with COVID-19 ARDS. Chest. 2020 Oct;158(4):A617. doi: 10.1016/j.chest.2020.08.58.
Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017 Jul;39(5):529-539. doi: 10.1007/s00281-017-0629-x.
Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol. 2017 Jul;39(5):517-528. doi: 10.1007/s00281-017-0639-8.
Luo W, Li YX, Jiang LJ, Chen Q, Wang T, Ye DW. Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19. Trends Pharmacol Sci. 2020 Aug;41(8):531-543. doi: 10.1016/j.tips.2020.06.007.
Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L, Huang L, Meng F, Huang L, Wang N, Zhou X, Luo H, Mao Z, Chen X, Xie J, Liu J, Cheng H, Zhao J, Huang G, Wang W, Zhou J. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol. 2020 Jul;146(1):137-146.e3. doi: 10.1016/j.jaci.2020.05.019.
Iastrebner M. Ruxolitinib in the Treatment of Covid-19. ClinicalTrials.gov registration number: NCT04414098. 2020 Jun. Available in: https://clinicaltrials.gov/ct2/show/NCT04414098
National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), V5.0. 2017 Nov. Available at: https://bit.ly/33NS3FN (last accessed Dec 2nd, 2020).
RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436.
COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at: https://bit.ly/3oNtWiD
World Health Organization. Novel Coronavirus: COVID-19 Therapeutic Trial Synopsis. Switzerland: WHO. R&D Blueprint. 2020 Available at: https://bit.ly/36JbdhV
Royal College of Physicians. National Early Warning Score (NEWS) 2. 2017 Dec. Available at: https://bit.ly/3lLYejY
Ministerio de Salud de la Nación. Guía para Investigaciones con Seres Humanos. Resolución 1480/2011. Available at: http://www.anmat.gov.ar/webanmat/legislacion/medicamentos/Resolucion_1480-2011.pdf
Protección de los Datos Personales. Ley 25326. Ministerio de Justicia y Derechos Humanos. Prom 2000 Oct 30. Available at: http://servicios.infoleg.gob.ar/infolegInternet/anexos/60000-64999/64790/texact.htm
Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: The reality and challenges. J Microbiol Immunol Infect. 2020 Jun;53(3):436-443. doi: 10.1016/j.jmii.2020.03.034.
La Rosée F, Bremer HC, Gehrke I, Kehr A, Hochhaus A, Birndt S, Fellhauer M, Henkes M, Kumle B, Russo SG, La Rosée P. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia. 2020 Jul;34(7):1805-1815. doi: 10.1038/s41375-020-0891-0.
Capochiani E, Frediani B, Iervasi G, Paolicchi A, Sani S, Roncucci P, Cuccaro A, Franchi F, Simonetti F, Carrara D, Bertaggia I, Nasso D, Riccioni R, Scolletta S, Valente S, Conticini E, Gozzetti A, Bocchia M. Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol. Front Med (Lausanne). 2020 Aug 4;7:466. doi: 10.3389/fmed.2020.00466..
Vannucchi AM, Sordi B, Morettini A, Nozzoli C, Poggesi L, Pieralli F, Bartoloni A, Atanasio A, Miselli F, Paoli C, Loscocco GG, Fanelli A, Para O, Berni A, Tassinari I, Zammarchi L, Maggi L, Mazzoni A, Scotti V, Falchetti G, Malandrino D, Luise F, Millotti G, Bencini S, Capone M, Piccinni MP, Annunziato F, Guglielmelli P; RUXO-COVID Study Group. Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study. Leukemia. 2021 Apr;35(4):1121-1133. doi: 10.1038/s41375-020-01018-y.
Novartis Press Release: Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19. 2020 Dec 14. Available at: http://bit.ly/39rTH3r
Fioranelli M, Roccia MG, Lotti T. Treatment of dermatomyositis with ruxolitinib. Dermatol Ther. 2016 Jul;29(4):285. doi: 10.1111/dth.12308.
Aeschlimann FA, Frémond ML, Duffy D, Rice GI, Charuel JL, Bondet V, Saire E, Neven B, Bodemer C, Balu L, Gitiaux C, Crow YJ, Bader-Meunier B. A child with severe juvenile dermatomyositis treated with ruxolitinib. Brain. 2018 Nov 1;141(11):e80. doi: 10.1093/brain/awy255. Erratum in: Brain. 2019 Jan 1;142(1):e3.
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032..
Amgalan A, Othman M. Hemostatic laboratory derangements in COVID-19 with a focus on platelet count. Platelets. 2020 Aug 17;31(6):740-745. doi: 10.1080/09537104.2020.1768523.
Amaratunga EA, Corwin DS, Moran L, Snyder R. Bradycardia in Patients With COVID-19: A Calm Before the Storm? Cureus. 2020 Jun 13;12(6):e8599. doi: 10.7759/cureus.8599
Merino JL, Martínez-Cossiani M, Iniesta A, Escobar C, Rey JR, Castrejón-Castrejón S. COVID-19 and QT interval prolongation: more than just drug toxicity? Europace. 2020 Oct 1;22(10):1479. doi: 10.1093/europace/euaa145.
Agarwal A, Chen A, Ravindran N, To C, Thuluvath PJ. Gastrointestinal and Liver Manifestations of COVID-19. J Clin Exp Hepatol. 2020 May-Jun;10(3):263-265. doi: 10.1016/j.jceh.2020.03.001.
Wang Q, Zhao H, Liu LG, Wang YB, Zhang T, Li MH, Xu YL, Gao GJ, Xiong HF, Fan Y, Cao Y, Ding R, Wang JJ, Cheng C, Xie W. Pattern of liver injury in adult patients with COVID-19: a retrospective analysis of 105 patients. Mil Med Res. 2020 Jun 7;7(1):28. doi: 10.1186/s40779-020-00256-6.
Aloysius MM, Thatti A, Gupta A, Sharma N, Bansal P, Goyal H. COVID-19 presenting as acute pancreatitis. Pancreatology. 2020 Jul;20(5):1026-1027. doi: 10.1016/j.pan.2020.05.003.
Komar HM, Serpa G, Kerscher C, Schwoegl E, Mace TA, Jin M, Yang MC, Chen CS, Bloomston M, Ostrowski MC, Hart PA, Conwell DL, Lesinski GB. Inhibition of Jak/STAT signaling reduces the activation of pancreatic stellate cells in vitro and limits caerulein-induced chronic pancreatitis in vivo. Sci Rep. 2017 May 11;7(1):1787. doi: 10.1038/s41598-017-01973-0.
Clancy CJ, Nguyen MH. Coronavirus Disease 2019, Superinfections, and Antimicrobial Development: What Can We Expect? Clin Infect Dis. 2020 Dec 17;71(10):2736-2743. doi: 10.1093/cid/ciaa524.
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Universidad Nacional de Córdoba
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The Faculty of Medical Sciences Journal (RFCM) subscribes to the Open Access policy and does not charge authors fees for publishing, nor does it charge readers fees for accessing published articles (APC).
